Medical Pharmacology: Immunopharmacology (Immunosuppressants/Immunomodulators) Practice Questions
Golimumab (Simponi)
Click on the correct answer.
Golimumab (Simponi):
Monoclonal antibody
Directed against TNF-α
Both
Neither
Golimumab (Simponi): may be in used as monotherapy or in combination with methotrexate
for:
Active psoriatic arthritis
Moderately-severely active rheumatoid arthritis.
Both
Neither
Golimumab:
Human IgG1κ monoclonal antibody
produced by mouse hybridoma cells utilizing recombinant DNA methods.
Useful in treating psoriatic arthritis along with axial spondyloarthritis (ankylosing spondylitis
along with non-radiographic axial spondyloarthritis).
Both
Neither
In rheumatoid arthritis:
Golimumab mode of action is mainly targeting and then neutralizing TNF-α
Golimumab
pharmacological efficacy is based on inflammation prevention as well as limiting cartledge degradation and bone destruction.
Both
Neither
Golimumab pharmacokinetics:
Dose-proportional pharmacokinetics i.e. (dosage approaches based on body weight)
Time to maximum plasma concentration following single subcutaneous administration is in the range of 2-7 days
Both
Neither
Golimumab pharmacokinetics:
Steady-state plasma drug levels: may be obtained in about 3 months using repetitive interactions.
Bioavailability is estimated at 50%.
Both
Neither
Golimumab (Simponi) may be used to treat moderately to severe, active, ulcerative colitis.
True
Activation of TNF-α receptors, especially TNF receptor 1:
Activates a signaling pathway leading to stimulation of nuclear factor-κ B receptor (NFKB) that translocates to the nucleus.
Nuclear factor-κ B receptor
promotes transcription of pro-inflammatory cytokine genes.
Both
Neither
Golimumab pharmacokinetics:
Volume of distribution was estimated is about
2 times plasma volume.
Golimumab appears mainly localized in the circulatory system with some extravascular tissue presence.
If you wish to return to the Table of Contents
in ENGLISH, press the RETURN button above.
Otherwise, if the text is NOT displayed in
English and you are ready to leave this page,
Press here
to return to the Table of Contents
Source Material:
Rothlin C Gutkind J Chapter 39
Immunosuppressants, Immunomodulation and Tolerance In
Goodman & Gilman's The Pharmacological Basis of Therapeutics
(Brunton LL Knollman BC eds) McGraw Hill LLC (2023).
Lake D & Briggs A Ch 55 Immunopharmacology
in Katzung's Basic & Clinical Pharmacology (Vanderah TW, ed)
16e McGraw Hill 2023.
Chrouos G Ch 39 Adrenocorticosteroids &
Adrenocortical Antagonists in Katzung's Basic & Clinical
Pharmacology (Vanderah TW, ed) 16e McGraw Hill 2023
Brezinski E Klickstein L Armstrong A Ch 46
Pharmacology of Immunosuppression in Principles of
Pharmacology: The Pathophysiologic Basis of Drug Therapy.
(Golan DE Armstrong EJ Armstrong AW, eds) 4e 2017 ls) 4e
2017
Ritter JM Flower R Henderson G Loke YK
MacEwan D Robinson E Fullerton J Ch 25 Anti-inflammatory and
Immunosuppressant Drugs Rang & Dale's Pharmacology 10e
Elsevier 2024.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 72 Immunosuppressants Elsevier 2022.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 75 Glucocorticoids in Nonendrocrine
Disorders Elsevier 2022.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 76 Drug Therapy for Rheumatoid Arthritis
Elsevier 2022.
Bass A Rogatsky Ch 32 Immunomodulatory Drugs
in Goldman-Cecil Medicine (Goldman L Schafer, eds) Elsevier
26e 2020
Leiva M Takemoto Ch 238 Immunosuppressants in
Lippincott Illustrated Reviews: Pharmacology 8e ((Walen et
al, eds) Wolters Kluwer 2023.
Hall J Hall M Ch 78 Adrenocortical
Hormones Guyton and Hall Textbook of Medical Physiology 14e
Elsevier 2021.
Waller DG Sampson A Hitchings Ch 38 The
Immune Response and Immunosuppressant Drugs
Medical Pharmacology & Therapeutics 6e Elsevier 2022
Waller DG Sampson A Hitchings Ch 30
Rheumotoid Arthritis, Other Inflammatory Arthrides and
Osteoarthritis Medical Pharmacology & Therapeutics 6e
Elsevier 2022
